What is Zolinza’s effect on myeloma?
Zolinza’s myeloma effects have been shown by adding Zolinza to Velcade (bortezomib), Revlimid (lenalidomide), or Thalomid (thalidomide). This combination has resulted in responses to relapsed or refractory multiple myeloma.
The combination of Zolinza and Velcade provided higher response rates, but not clinically significant improvement in disease progression or survival, compared to Velcade alone in a Phase III trial.
This trial included 637 patients who had received an average of 2 previous therapies.
The overall response rate seen with Zolinza and Velcade was significantly higher than that seen with Velcade alone (56% vs. 41%).
Combination therapy with Zolinza and Velcade significantly prolonged average time without myeloma disease progression compared with Velcade alone (7.6 months versus 6.8 months). However, this difference is relatively small.
At the current time, there is no difference in survival between the two treatment groups.
The most common severe side effects seen in both study arms included low blood cell and platelet counts, diarrhea, and fatigue.
Based on these results and those of an earlier trial that showed an improved overall response rate with Zolinza and Velcade compared with Velcade alone, this combination is now listed as a treatment option for relapsed/refractory myeloma in myeloma treatment guidelines.
Zolinza has also been evaluated as part of combination therapy in newly diagnosed myeloma.
Results of a Phase I trial that added Zolinza to Revlimid, Velcade and dexamethasone are promising. Ninety-seven percent of the 30 patients enrolled in the study responded to therapy, with 30% achieving a stringent complete response and 10% achieving a complete response or near complete response. No unexpected side effects were noted.